Understand the source comparison
Kisspeptin Fertility Complete Guide 2026: Comparison of Clinical Protocols and Research Applications
This table compares the most studied kisspeptin protocols, their target populations, administration routes, and documented outcomes. Ovulation Induction (Hypothalamic Amenorrhea) Women with functional hypothalamic amenorrhea (HA), BMI 18.5–25 Kisspeptin-54, 6.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- This table compares the most studied kisspeptin protocols, their target populations, administration routes, and documented outcomes.
- Ovulation Induction (Hypothalamic Amenorrhea)
- Women with functional hypothalamic amenorrhea (HA), BMI 18.5–25
- Kisspeptin-54, 6.4 nmol/kg twice weekly
- Subcutaneous
- 8–12 weeks
- Ovulation confirmed by mid-luteal progesterone >10 ng/mL; 74% response rate in Phase 2 trials
- Most physiological approach for HA. Avoids pituitary desensitization seen with pulsatile GnRH pumps
- IVF Trigger (OHSS Prevention)
- Women undergoing IVF with >15 follicles (high OHSS risk)
- Kisspeptin-54, 9.6–12.8 nmol/kg single bolus
- Intravenous
- Single dose 36 hours pre-retrieval
- LH surge within 10–12 hours; zero moderate-to-severe OHSS cases vs 15% with hCG
- Superior safety profile in high responders; pregnancy rates equivalent to hCG
- Male Hypogonadism (Testosterone Restoration)
- Men with congenital hypogonadotropic hypogonadism (CHH)
- 12–24 weeks
- Testosterone increase to 350–550 ng/dL in 70% of participants; requires continuous dosing
- Restores endogenous production without testicular atrophy. Unlike exogenous testosterone
- Pubertal Induction
- Adolescents with delayed puberty due to hypogonadotropic hypogonadism
- Kisspeptin-54, escalating dose 1.0–6.4 nmol/kg
- Subcutaneous or IV
- 6–12 months
- Testicular volume increase, breast development (Tanner staging), and bone age advancement
- Early-phase research; less invasive than pulsatile GnRH but requires long-term adherence